Artios

Developing the next generation DNA Damage Repair treatments for cancer with first and best-in-class pipeline

Artios is on a mission to kill cancer by exploiting DNA damage repair (DDR) responses that are leveraged by cancer cells to promote their survival. The DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. Artios pipeline is designed to address areas of high unmet needs across solid tumour indications including ATR inhibitor and Polθ inhibitor as a monotherapy and with combination treatments. Together with their world-class strategic partnerships with Merck KGaA, Darmstadt, Germany  and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute, Artios is pioneering validated approaches to DDR drug discovery.